CoChat

Super enhancer regulation of cytokine-induced chemokine production in alcoholic hepatitis

Open access

The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.

Abstract

Alcoholic hepatitis (AH) is associated with liver neutrophil infiltration through activated cytokine pathways leading to elevated chemokine expression. Super-enhancers are expansive regulatory elements driving augmented gene expression. Here, we explore the mechanistic role of super-enhancers linking cytokine TNFα with chemokine amplification in AH. RNA-seq and histone modification ChIP-seq of human liver explants show upregulation of multiple CXCL chemokines in AH. Liver sinusoidal endothelial cells (LSEC) are identified as an important source of CXCL expression in human liver, regulated by TNFα/NF-κB signaling. A super-enhancer is identified for multiple CXCL genes by multiple approaches. dCas9-KRAB-mediated epigenome editing or pharmacologic inhibition of Bromodomain and Extraterminal (BET) proteins, transcriptional regulators vital to super-enhancer function, decreases chemokine expression in vitro and decreases neutrophil infiltration in murine models of AH. Our findings highlight the role of super-enhancer in propagating inflammatory signaling by inducing chemokine expression and the therapeutic potential of BET inhibition in AH treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-021-24843-w

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 RNA-seq and histone mark ChIP-seq of AH and normal livers show significant differences. a Schematic of RNA-seq and ChIP-seq analyses pipeline. b Heatmap of differentially expressed genes from the integrated analysis of RNA-seq and ChIP-seq (gold: upregulated genes; green: downregulated genes). c IPA of upregulated genes from the integrated analysis. Top ten affected canonical pathways are listed along with their respective inverse log of p values. Right-tailed Fisher’s Exact Test was used for the calculation of p values. d Differentially expressed genes from the granulocytes/agranulocytes adhesion and diapedesis pathways are listed. Four CXCL chemokines 1, 5, 6, and 8 are located at the same locus and are colored light gray. e Upstream regulator analysis from IPA. Top ten activated upstream regulators are listed along with their respective normalized z-scores. f GSEA of TNFα and NF-κB pathway target genes. AH enriched genes are plotted to the left and control enriched genes are plotted to the right. Normalized enrichment score (NES) and false discovery rate (FDR) are listed for the analyses.
Fig. 1 RNA-seq and histone mark ChIP-seq of AH and normal livers show significant differences. a Schematic of RNA-seq and ChIP-seq analyses pipeline. b Heatmap of differentially expressed genes from the integrated analysis of RNA-seq and ChIP-seq (gold: upregulated genes; green: downregulated genes). c IPA of upregulated genes from the integrated analysis. Top ten affected canonical pathways are listed along with their respective inverse log of p values. Right-tailed Fisher’s Exact Test was used for the calculation of p values. d Differentially expressed genes from the granulocytes/agranulocytes adhesion and diapedesis pathways are listed. Four CXCL chemokines 1, 5, 6, and 8 are located at the same locus and are colored light gray. e Upstream regulator analysis from IPA. Top ten activated upstream regulators are listed along with their respective normalized z-scores. f GSEA of TNFα and NF-κB pathway target genes. AH enriched genes are plotted to the left and control enriched genes are plotted to the right. Normalized enrichment score (NES) and false discovery rate (FDR) are listed for the analyses.CC BY · PubMed Central
Fig. 2 LSECs are a major source of CXCL chemokines in the liver under the control of TNFα/NF-κB signaling. a RNA-seq of normal liver cell types. Expression levels of CXCL genes (expressed in RPKM) were normalized (see supplemental methods for normalization details) and ratios are plotted. Data represented as mean ± SD. One-way ANOVA analysis was performed, with post hoc Dunnett’s multiple comparison correction (n = 3 biologically independent samples for each cell type). b TNFα significantly increased expression of CXCL chemokines revealed by qPCR (n = 4, biologically independent samples from two independent experiments, experiments repeated more than five times with similar results) and by ELISA (n = 11, biologically independent samples from three independent experiments). CXCL chemokines expression is shown as fold change over control condition for qPCR and as pg/ml by ELISA. Data represented as mean ± SD. A two-sided, paired t-test analysis was performed. c LSECs were pretreated with varying amounts of Celastrol (0 to 5 μM) and exposed to medium with or without TNFα. qPCRs were performed for quantifying the expression of CXCL1, 6, and 8, and shown in log10 fold over basal expression. Data represented as mean ± SD. One-way matched-pairs ANOVA analysis was performed with post hoc Dunnett’s multiple comparison correction (n = 6, biologically independent samples from three independent experiments). There was a significant linear trend of decreasing CXCL1, 6, 8 expressions with increasing Celastrol concentrations with TNFα (p < 0.0001 for all groups).
Fig. 2 LSECs are a major source of CXCL chemokines in the liver under the control of TNFα/NF-κB signaling. a RNA-seq of normal liver cell types. Expression levels of CXCL genes (expressed in RPKM) were normalized (see supplemental methods for normalization details) and ratios are plotted. Data represented as mean ± SD. One-way ANOVA analysis was performed, with post hoc Dunnett’s multiple comparison correction (n = 3 biologically independent samples for each cell type). b TNFα significantly increased expression of CXCL chemokines revealed by qPCR (n = 4, biologically independent samples from two independent experiments, experiments repeated more than five times with similar results) and by ELISA (n = 11, biologically independent samples from three independent experiments). CXCL chemokines expression is shown as fold change over control condition for qPCR and as pg/ml by ELISA. Data represented as mean ± SD. A two-sided, paired t-test analysis was performed. c LSECs were pretreated with varying amounts of Celastrol (0 to 5 μM) and exposed to medium with or without TNFα. qPCRs were performed for quantifying the expression of CXCL1, 6, and 8, and shown in log10 fold over basal expression. Data represented as mean ± SD. One-way matched-pairs ANOVA analysis was performed with post hoc Dunnett’s multiple comparison correction (n = 6, biologically independent samples from three independent experiments). There was a significant linear trend of decreasing CXCL1, 6, 8 expressions with increasing Celastrol concentrations with TNFα (p < 0.0001 for all groups).CC BY · PubMed Central
Fig. 3 Identification of a super-enhancer for CXCL chemokines. a 4 C was performed on LSEC cells with and without TNFα stimulation. Interactions with the CXCL1 promoter were plotted using read counts. A genome region of about 75 kb contained two peaks of CXCL1 interaction under TNFα stimulation (red box). Viewpoint (VP) was labeled with a blackline indicating the location of the reference sequence. b H3K27ac and H3K4me1 ChIP-seq signals of normal (blue) and AH (red) livers were plotted. The black dot indicates the location of the NF-κB site (E1) targeted for subsequent analyses. Scale bar represents 50 kb. c ChIP-qPCR assays for BRD4 and NF-κB binding at the aforementioned locus (black dot). Sequence enrichment was normalized to input. Data represented as mean ± SD. A two-sided, paired t-test was performed on percent input values (n = 8, biologically independent samples from three independent experiments). d, e ROSE algorithm of putative super-enhancer analysis from LSECs without (d) or with (e) TNFα treatment. The region contained in the orange dashed box contained sequences with top H3K27ac enrichment and are considered to be putative super-enhancers. f 3 C experiments were performed on LSECs to detect an interaction of the predicted CXCL super-enhancer with promoters of various CXCLs without (thick line) and with TNFα (thin line). The aforementioned NF-κB binding site (black dot) within the CXCL super-enhancer (dash lines) was used as a reference sequence. Interaction frequencies were plotted after normalized to that of RASSF6, a nearby noninflammatory gene used as control. Multiple other sequences were selected between target CXCL promoters as additional controls. X-axis maps relevant gene sequences as distance (in kb) from RASSF6. Two-way paired ANOVA analysis was performed on the relative interaction frequencies at target sites followed by post hoc Sidak’s multiple comparison correction (n = 4, biologically independent samples from three independent experiments). Data represented as mean ± SD. Treatment with TNFα was found to be a significant variable (p = 0.0034). CXCL1, 2, 3, 6, and 8 loci were found to have increased interaction frequencies with p values as labeled.
Fig. 3 Identification of a super-enhancer for CXCL chemokines. a 4 C was performed on LSEC cells with and without TNFα stimulation. Interactions with the CXCL1 promoter were plotted using read counts. A genome region of about 75 kb contained two peaks of CXCL1 interaction under TNFα stimulation (red box). Viewpoint (VP) was labeled with a blackline indicating the location of the reference sequence. b H3K27ac and H3K4me1 ChIP-seq signals of normal (blue) and AH (red) livers were plotted. The black dot indicates the location of the NF-κB site (E1) targeted for subsequent analyses. Scale bar represents 50 kb. c ChIP-qPCR assays for BRD4 and NF-κB binding at the aforementioned locus (black dot). Sequence enrichment was normalized to input. Data represented as mean ± SD. A two-sided, paired t-test was performed on percent input values (n = 8, biologically independent samples from three independent experiments). d, e ROSE algorithm of putative super-enhancer analysis from LSECs without (d) or with (e) TNFα treatment. The region contained in the orange dashed box contained sequences with top H3K27ac enrichment and are considered to be putative super-enhancers. f 3 C experiments were performed on LSECs to detect an interaction of the predicted CXCL super-enhancer with promoters of various CXCLs without (thick line) and with TNFα (thin line). The aforementioned NF-κB binding site (black dot) within the CXCL super-enhancer (dash lines) was used as a reference sequence. Interaction frequencies were plotted after normalized to that of RASSF6, a nearby noninflammatory gene used as control. Multiple other sequences were selected between target CXCL promoters as additional controls. X-axis maps relevant gene sequences as distance (in kb) from RASSF6. Two-way paired ANOVA analysis was performed on the relative interaction frequencies at target sites followed by post hoc Sidak’s multiple comparison correction (n = 4, biologically independent samples from three independent experiments). Data represented as mean ± SD. Treatment with TNFα was found to be a significant variable (p = 0.0034). CXCL1, 2, 3, 6, and 8 loci were found to have increased interaction frequencies with p values as labeled.CC BY · PubMed Central
Fig. 4 Histone modifications at CXCL super-enhancer and CXCL promoter sites modulate chemokine gene expression. a Schematic of dCas9-KRAB binding with sgRNA leading to epigenetic silencing. b dCas9-KRAB fusion protein targeting the selected NFκB site within CXCL super-enhancer suppressed CXCL expression in LSECs. A sgRNA with specificity for a predicted NFκB binding site on the CXCL enhancer decreased CXCL1, 6, and 8 expressions revealed by qPCR but did not affect the expression of MTHFD2L, a nearby noninflammatory gene (negative control) (n = 8, biologically independent samples from four independent experiments). Changes in chemokine expression were calculated as fold change over basal expression and log10 (fold change) was plotted on the y-axis. ELISA for CXCL1 was performed on supernatants and mirrored the pattern seen from qPCR (n = 6, biologically independent samples from three independent experiments). Data represented as mean ± SD. Two-way matched-pairs ANOVA was performed on log-transformed fold change values with post hoc Tukey’s multiple comparison correction. c Another sgRNA targeting a predicted NF-κB binding site on CXCL1 promoter decreased expression of CXCL1, but not other CXCLs by qPCR (n = 8, biologically independent samples from four independent experiments) and CXCL1 ELISA (n = 6, biologically independent samples from three independent experiments). Log10 (fold change) was plotted. Data represented as mean ± SD. Two-way matched-pairs ANOVA was performed on log-transformed fold change values, with post hoc Tukey’s multiple comparison correction. d ChIP-qPCR for H3K9me3 on dCas9-KRAB treated cells. dCas9-KRAB was co-transduced with sgRNA targeting CXCL promoter (P), CXCL super-enhancer (E), or empty vector (C), and treated with or without TNFα. ChIP-qPCR was performed with anti-H3K9me3 antibody or isotype control. Enrichment for either CXCL1 promoter or CXCL super-enhancer sequence was examined. Y-axis plots percent input (n = 3 from biologically independent samples). Data represented as mean ± SD. Two-way matched-pairs ANOVA was performed with post hoc Dunnett’s multiple comparison correction.
Fig. 4 Histone modifications at CXCL super-enhancer and CXCL promoter sites modulate chemokine gene expression. a Schematic of dCas9-KRAB binding with sgRNA leading to epigenetic silencing. b dCas9-KRAB fusion protein targeting the selected NFκB site within CXCL super-enhancer suppressed CXCL expression in LSECs. A sgRNA with specificity for a predicted NFκB binding site on the CXCL enhancer decreased CXCL1, 6, and 8 expressions revealed by qPCR but did not affect the expression of MTHFD2L, a nearby noninflammatory gene (negative control) (n = 8, biologically independent samples from four independent experiments). Changes in chemokine expression were calculated as fold change over basal expression and log10 (fold change) was plotted on the y-axis. ELISA for CXCL1 was performed on supernatants and mirrored the pattern seen from qPCR (n = 6, biologically independent samples from three independent experiments). Data represented as mean ± SD. Two-way matched-pairs ANOVA was performed on log-transformed fold change values with post hoc Tukey’s multiple comparison correction. c Another sgRNA targeting a predicted NF-κB binding site on CXCL1 promoter decreased expression of CXCL1, but not other CXCLs by qPCR (n = 8, biologically independent samples from four independent experiments) and CXCL1 ELISA (n = 6, biologically independent samples from three independent experiments). Log10 (fold change) was plotted. Data represented as mean ± SD. Two-way matched-pairs ANOVA was performed on log-transformed fold change values, with post hoc Tukey’s multiple comparison correction. d ChIP-qPCR for H3K9me3 on dCas9-KRAB treated cells. dCas9-KRAB was co-transduced with sgRNA targeting CXCL promoter (P), CXCL super-enhancer (E), or empty vector (C), and treated with or without TNFα. ChIP-qPCR was performed with anti-H3K9me3 antibody or isotype control. Enrichment for either CXCL1 promoter or CXCL super-enhancer sequence was examined. Y-axis plots percent input (n = 3 from biologically independent samples). Data represented as mean ± SD. Two-way matched-pairs ANOVA was performed with post hoc Dunnett’s multiple comparison correction.CC BY · PubMed Central
Fig. 5 Bromodomain inhibitors suppress the expression of CXCLs by inhibition of transcription factor binding at CXCL super-enhancer and promoter sites. a, b LSECs were pretreated with iBET151 (0–50 μM) (n = 4, biologically independent samples from two independent experiments) (a) or UMN627 (0–50 μM) (n = 5, biologically independent samples from three independent experiments) (b). CXCL1, 6, and 8 expression levels were assessed by qPCR. Expression levels were normalized to basal conditions and log10 fold change values were plotted. One-way matched-pairs ANOVA analysis was performed with post hoc Dunnett’s multiple comparison correction. Data represented as mean ± SD. c, d ChIP-qPCR assays for BRD4 binding (c, n = 4, biologically independent samples from two independent experiments) or NF-κB binding (d, n = 6, biologically independent samples from three independent experiments) with and without TNFα stimulation was assessed at CXCL super-enhancer and CXCL1 promoter sites after pretreatment with iBET151. One-way ANOVA analysis was performed with post hoc Tukey’s multiple comparison correction. Data represented as mean ± SD. e, f Same experiments were repeated with Celastrol (e, n = 4 biologically independent samples from two independent experiments; f, n = 6 biologically independent samples from three independent experiments). Enrichment for either CXCL1 promoter or CXCL super-enhancer sequence was examined. Sequence enrichment was normalized to input. One-way ANOVA analysis was performed with post hoc Tukey’s multiple comparison correction. Data represented as mean ± SD. There were significant linear trends of decreasing CXCL1, 6, 8 expressions with increasing iBET151 and UMN627 concentrations without and with TNFα, and with increasing iBET151 concentrations without TNFα (p < 0.0001 for all groups). All data were repeated at least three times with similar results.
Fig. 5 Bromodomain inhibitors suppress the expression of CXCLs by inhibition of transcription factor binding at CXCL super-enhancer and promoter sites. a, b LSECs were pretreated with iBET151 (0–50 μM) (n = 4, biologically independent samples from two independent experiments) (a) or UMN627 (0–50 μM) (n = 5, biologically independent samples from three independent experiments) (b). CXCL1, 6, and 8 expression levels were assessed by qPCR. Expression levels were normalized to basal conditions and log10 fold change values were plotted. One-way matched-pairs ANOVA analysis was performed with post hoc Dunnett’s multiple comparison correction. Data represented as mean ± SD. c, d ChIP-qPCR assays for BRD4 binding (c, n = 4, biologically independent samples from two independent experiments) or NF-κB binding (d, n = 6, biologically independent samples from three independent experiments) with and without TNFα stimulation was assessed at CXCL super-enhancer and CXCL1 promoter sites after pretreatment with iBET151. One-way ANOVA analysis was performed with post hoc Tukey’s multiple comparison correction. Data represented as mean ± SD. e, f Same experiments were repeated with Celastrol (e, n = 4 biologically independent samples from two independent experiments; f, n = 6 biologically independent samples from three independent experiments). Enrichment for either CXCL1 promoter or CXCL super-enhancer sequence was examined. Sequence enrichment was normalized to input. One-way ANOVA analysis was performed with post hoc Tukey’s multiple comparison correction. Data represented as mean ± SD. There were significant linear trends of decreasing CXCL1, 6, 8 expressions with increasing iBET151 and UMN627 concentrations without and with TNFα, and with increasing iBET151 concentrations without TNFα (p < 0.0001 for all groups). All data were repeated at least three times with similar results.CC BY · PubMed Central
Fig. 6 Bromodomain inhibitor iBET151 attenuates liver CXCL production and neutrophil infiltration in a murine alcohol feeding/LPS model. a Schematic of alcohol feeding protocol. Mice were fed a 5% alcohol diet or a pair-fed control diet for 10 days. A subset of mice also received IP injection of the iBET151 compound. Alcohol-fed mice also received IP injection of LPS on day 11, 8 h before sacrifice (n = 12 pair-fed/Veh, n = 14 EtOH+LPS/Veh, n = 8 Pair-fed/iBET151, n = 6 EtOH+LPS/iBET151, same n for remaining panels of this figure). b qPCRs demonstrated CXCL chemokine and neutrophil marker Ly6g elevation with alcohol/LPS treatment. This response was attenuated by iBET151 injections. Expression levels were normalized to the average expression of pair-fed control mice. c IHC for MPO (neutrophil marker) is shown, with a number of neutrophils per low power field on the y-axis. The experiment was repeated with similar results. Scale bar = 100 μm. d Frozen section of mouse liver was stained with BODIPY 493/503 (green) and DAPI was used to stain nuclei (blue). The experiment was repeated with similar results. Scale bar = 100 μm. e No statistical difference was noted in serum ALT levels among groups. f Quantification of Western Blotting of cleaved caspase3 showed increased cleaved caspase 3 in livers of alcohol-fed/LPS mice and attenuated by iBET151 injection. For all analysis, two-way ANOVA was performed on normalized expression values for qPCRs, cell counts for IHC staining, normalized quantification of BODIPY 493/503 staining, ALT values, or quantification of WB bands with post hoc Tukey’s multiple comparison correction. Data represented as mean ± SD.
Fig. 6 Bromodomain inhibitor iBET151 attenuates liver CXCL production and neutrophil infiltration in a murine alcohol feeding/LPS model. a Schematic of alcohol feeding protocol. Mice were fed a 5% alcohol diet or a pair-fed control diet for 10 days. A subset of mice also received IP injection of the iBET151 compound. Alcohol-fed mice also received IP injection of LPS on day 11, 8 h before sacrifice (n = 12 pair-fed/Veh, n = 14 EtOH+LPS/Veh, n = 8 Pair-fed/iBET151, n = 6 EtOH+LPS/iBET151, same n for remaining panels of this figure). b qPCRs demonstrated CXCL chemokine and neutrophil marker Ly6g elevation with alcohol/LPS treatment. This response was attenuated by iBET151 injections. Expression levels were normalized to the average expression of pair-fed control mice. c IHC for MPO (neutrophil marker) is shown, with a number of neutrophils per low power field on the y-axis. The experiment was repeated with similar results. Scale bar = 100 μm. d Frozen section of mouse liver was stained with BODIPY 493/503 (green) and DAPI was used to stain nuclei (blue). The experiment was repeated with similar results. Scale bar = 100 μm. e No statistical difference was noted in serum ALT levels among groups. f Quantification of Western Blotting of cleaved caspase3 showed increased cleaved caspase 3 in livers of alcohol-fed/LPS mice and attenuated by iBET151 injection. For all analysis, two-way ANOVA was performed on normalized expression values for qPCRs, cell counts for IHC staining, normalized quantification of BODIPY 493/503 staining, ALT values, or quantification of WB bands with post hoc Tukey’s multiple comparison correction. Data represented as mean ± SD.CC BY · PubMed Central
Fig. 7 Bromodomain inhibitor UMN627 attenuates liver CXCL production and neutrophil infiltration in an alcohol binge/LPS model. a Schematic of alcohol binge/LPS model protocol. Mice underwent once-daily gastric gavage with alcohol or maltose dextran for 3 days. A subset of mice also received IP injection of UMN627. Alcohol-gavaged mice also received IP injection of LPS on day 4, 8 h before sacrifice (n = 7 Control/Veh, n = 10 Binge + LPS/Veh, n = 7 Control/UMN627, n = 12 Binge+LPS/UMN627, same n for remaining panels of this figure). b qPCRs demonstrated CXCL chemokine and neutrophil marker Ly6g expression elevation with alcohol/LPS treatment. This response was attenuated by UMN627. Expression levels were normalized to the average expression of maltose gavaged control mice. c IHC for MPO is shown, with a number of neutrophils per low power field on the y-axis. The experiment was repeated with similar results. d Frozen section of mouse liver was stained with BODIPY 493/503 (green) and DAPI was used to stain nuclei (blue). The experiment was repeated with similar results. e Serum ALT levels did not show statistical differences among various groups. For all analyses, two-way ANOVA was performed on normalized expression values for qPCRs, cell counts for IHC staining, normalized quantification of BODIPY 493/503 staining, or ALT values, with post hoc Tukey’s multiple comparison correction. Data represented as mean ± SD.
Fig. 7 Bromodomain inhibitor UMN627 attenuates liver CXCL production and neutrophil infiltration in an alcohol binge/LPS model. a Schematic of alcohol binge/LPS model protocol. Mice underwent once-daily gastric gavage with alcohol or maltose dextran for 3 days. A subset of mice also received IP injection of UMN627. Alcohol-gavaged mice also received IP injection of LPS on day 4, 8 h before sacrifice (n = 7 Control/Veh, n = 10 Binge + LPS/Veh, n = 7 Control/UMN627, n = 12 Binge+LPS/UMN627, same n for remaining panels of this figure). b qPCRs demonstrated CXCL chemokine and neutrophil marker Ly6g expression elevation with alcohol/LPS treatment. This response was attenuated by UMN627. Expression levels were normalized to the average expression of maltose gavaged control mice. c IHC for MPO is shown, with a number of neutrophils per low power field on the y-axis. The experiment was repeated with similar results. d Frozen section of mouse liver was stained with BODIPY 493/503 (green) and DAPI was used to stain nuclei (blue). The experiment was repeated with similar results. e Serum ALT levels did not show statistical differences among various groups. For all analyses, two-way ANOVA was performed on normalized expression values for qPCRs, cell counts for IHC staining, normalized quantification of BODIPY 493/503 staining, or ALT values, with post hoc Tukey’s multiple comparison correction. Data represented as mean ± SD.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 68 references

Cited by

See all 125

Metadata

Authors
Liu, M., Cao, S., He, L., Gao, J., Arab, J. P., Cui, H., Xuan, W., Gao, Y., Sehrawat, T. S., Hamdan, F. H., Ventura-Cots, M., Argemi, J., Pomerantz, W. C. K., Johnsen, S. A., Lee, J.-H., Gao, F., Ordog, T., Mathurin, P., Revzin, A., Bataller, R., Yan, H., & Shah, V. H.
Affiliations
  • Mayo Clinic (US)
  • Tongji Hospital (CN)
  • Sichuan University (CN)
  • Pontificia Universidad Católica de Chile (CL)
  • University of Minnesota (US)
  • Université de Lille (FR)
  • University of Pittsburgh (US)
Corresponding author
  • Yan, Huihuang
  • Shah, Vijay H.
Venue
Nature Communications
Published
2021-07-27
Volume
12
Issue
1
Pages
4560-4560
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3186731637
Cited by
120
References
68
Citations by year
2026: 18 · 2025: 28 · 2024: 26 · 2023: 34 · 2022: 13 · 2021: 1
FWCI
12.50
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, cc-by)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • LillOA (Université de Lille (University Of Lille)) (submittedVersion)
Funders
  • National Institutes of Health (DK59615, R01 DK59615, R01 AA21171)
  • National Institute on Alcohol Abuse and Alcoholism (R01AA021171)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK059615, P30DK084567)
Topics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords
alcoholic hepatitis, super-enhancers, chemokine expression, CXCL chemokines, TNF-α, NF-κB signaling, liver sinusoidal endothelial cells, BET proteins, epigenome editing, dCas9-KRAB, histone modifications, liver inflammation
MeSH terms
RNA-Seq, Animals, Disease Models, Animal, Enhancer Elements, Genetic, Gene Expression Regulation, Hepatitis, Alcoholic, Histones, Humans, Lipopolysaccharides, Liver, Mice, Inbred C57BL, Neutrophils, Promoter Regions, Genetic, Transcription Factors, Tumor Necrosis Factor-alpha, Signal Transduction, Cytokines, NF-kappa B, Chemokines, Endothelial Cells, Epigenesis, Genetic, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Super enhancer regulation of cytokine-induced chemokine production in alcoholic hepatitis. https://app.cochat.ai/papers/10.1038/s41467-021-24843-w
The paper
Liu, M., Cao, S., He, L., Gao, J., Arab, J. P., Cui, H., Xuan, W., Gao, Y., Sehrawat, T. S., Hamdan, F. H., Ventura-Cots, M., Argemi, J., Pomerantz, W. C. K., Johnsen, S. A., Lee, J.-H., Gao, F., Ordog, T., Mathurin, P., Revzin, A., . . . Shah, V. H. (2021). Super enhancer regulation of cytokine-induced chemokine production in alcoholic hepatitis. Nature Communications. https://doi.org/10.1038/s41467-021-24843-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.